Purity 99% GW0742 Sarms Powder CAS 317318-84-6 Sarms For Fat Loss

Purity 99% GW0742 Sarms Powder CAS 317318-84-6 Sarms For Fat Loss

What is GW0742?

GW0742 is a selective peroxisome proliferator-activated receptor (PPAR)-δ agonist, which is produced mainly in the liver and plays a key role in the breakdown of fatty acids. It is almost similar in structure to Cardarine but GW0742 is 200 times more potent and has more health benefits.

How does GW0742 Work?

As a PPAR delta agonist, GW0742 enhances fatty acid metabolism. This in turn preserves blood sugar as well as physical endurance. It is because of this effect that athletes, bodybuilders, and other physically active individuals use GW0742. Even in very small doses, GW0742 can significantly boost energy levels and stamina.

Research on GW0742

A. Promotes Muscle Regeneration and Increases Exercise Endurance

Studies suggest that GW0742 can help increase exercise endurance by promoting muscle regeneration:

1. 1. In a mouse model of muscle injury, GW0742 treatment resulted in faster skeletal muscle regeneration. 
   2. In trained mice, GW0742 treatment potentiated endurance and increased all running parameters. 
   3. In obese female mice, GW0742 increased endurance capacity by decreasing skeletal muscle inflammation. 
   4. In mice, GW0742 enhanced running endurance by 44%. 
   5. In mice, GW0742 induced an endurance-like oxidative muscle remodelling. 
   6. The injection of GW0742 in mice increased the formation of new blood vessels and heart muscle mass. 
   7. Studies reported that the pharmacological activation of PPARβ/δ by GW0742 increases the formation of new blood vessels and enhances the production of muscle fibers. 

B. Helps Lose Weight

By breaking down fatty acids, GW0742 improves body composition and helps lose weight:

1. 1. In obese female mice, regular exercise together with GW0742 treatment effectively reduced visceral adipose tissue mass and skeletal muscle inflammation. 
   2. In mice, it was shown that GW0742 and phillyrin (an anti-obesity agent) have similar weight-reducing effects. 
   3. In obese mice, GW0742 administration resulted in a modest reduction in fat mass. 
   4. In obese mice, GW0742 exerted preventive effects against obesity. 
   5. In diet-induced obese mice, GW0742 therapy induced a decrease in fat mass. 
   6. The administration of GW0742 in obese mice resulted in decreased body weight and food intake. 
   7. In obese male mice, GW0742 treatment for 4 weeks reduced the formation of fat cells. 

C. Lowers the Risk of Heart Disease

The ability of GW0742 to break down fatty acids produces beneficial effects on the heart, according to studies:

1. 1. In obese mice, GW0742 exerted protective effects against atherosclerosis (plaque formation within the heart arteries). 
   2. In rat heart tissue, GW0742 prevented heart enlargement due to high blood sugar levels by inhibiting free radicals. 
   3. A cell study found that GW0742 helps modulate signalling pathways associated with the growth of heart cells.
   4. In mice, GW0742 administration had direct protective effects against right ventricular hypertrophy (enlargement of the right ventricles). 
   5. In rats with pulmonary hypertension, daily oral administration of GW0742 prevented heart enlargement and normalized right heart pressures. 
   6. In neonatal rats, GW0742 treatment enhanced lipid metabolism in the heart. 

D. Accelerates Wound Healing

The regenerative properties of GW0742 are also backed by a number of studies:

1. 1. In murine models, GW0742 regulated endothelial cell behaviour and improved tissue maintenance and repair. 
   2. In rats, GW0742 promoted wound healing by modulating inflammation. 

E. Boosts Brain Power

Evidence suggests that GW0742 is integral for brain health:

1. 1. In mice, GW0742 treatment alleviated cognitive dysfunction caused by radiation. 
   2. In mice, it was shown that PPARδ activation alleviated brain toxicity induced by abnormal proteins known as beta amyloids. 
   3. A study reported that GW0742 plays an integral role in the maturation of brain cells. 
   4. In mice, GW0742 treatment successfully improved AD-related deficits by increasing fatty acid oxidation in astrocytes (cells in the central nervous system) and it also enhanced the cognition of the subjects. 
   5. In diabetic mice, oral administration with GW0742 for 2 weeks prevented deficits in spatial memory. 
   6. In rats exposed to global cerebral ischemia-reperfusion injury (insufficient blood flow to the brain), pretreatment with GW0742 exerted neuroprotective effects. 
   7. In mice, treatment with GW0742 significantly reduced cell death during a 12-hr exposure to low-KCl media. 
   8. In rats, GW0742 treated cognitive impairment due to insulin resistance and inflammation caused by high sugar intake. 
   9. In rats, GW0742 treatment prevented type 1 diabetes-induced cognitive impairment. 
   10. In mice, GW0742 treatment protected against brain dysfunction. 
   11. In a rodent model of Parkinson’s disease, injection with GW0742 exerted neuroprotective effects and prevented cognitive impairment. 
   12. In a mouse model of Alzheimer’s disease, oral treatment with GW0742 reduced abnormal brain proteins and proinflammatory mediators. 

F. Lowers Blood Pressure

GW0742 can also lower blood pressure which can be beneficial for the treatment of hypertension:

1. 1. In rats, GW0742 exhibited blood pressure-lowering effects and protected the blood vessels against injury. 
   2. In spontaneously hypertensive rats (SHR), GW0742 exerted anti-hypertensive effects while promoting better blood vessel function.

G. Improves Blood Sugar Levels and Treats Symptoms of Diabetes

Studies show that GW0742 can help stabilize blood sugar levels and can be considered an anti-diabetic agent:

1. 1. In diabetic mice, GW0742 was able to improve blood sugar homeostasis (balance) and was found to be a good candidate for the development of anti-diabetic drugs in the future. 
   2. In diabetic rats, daily injection of GW0742 prevented complications caused by diabetes. 
   3. In diabetic mouse models, oral administration of GW0742 improved T2DM-induced memory impairments. 
   4. In rats, GW0742 was able to mediate dilation changes during a diabetic state. 
   5. In obese mice, GW0742 improved blood sugar metabolism and gene regulatory responses. 
   6. In rats, GW0742 treatment led to improved insulin signaling. 
   7. In diabetic mice, GW0742 treatment protected against diabetes-induced kidney complications. 
   8. In diabetic mice, GW0742 prevented nerve damage associated with the disease. 

H. Treats Lung Injuries

A good deal of evidence shows that GW0742 can help protect the lungs against various forms of injury:

1. 1. In rats, daily oral treatment with GW0742 (30 mg/kg) for 3 weeks significantly reduced the increased pressure within the blood vessels of the lungs. 
   2. In mice, GW0742 prevented acute lung injuries and complications. 
   3. In a mouse model of emphysema (damage to the air sacs in the lungs), GW0742 repaired the collapsed alveoli. 
   4. In rats with lung injury caused by exposure to high levels of oxygen, GW0742 treatment prevented further lung damage. 
   5. The administration of GW0742 in mice reduced lung inflammation induced by bleomycin instillation. 

I. Improves Eye Health

The activation of PPARβ/δ by GW0742 produces beneficial effects on visual function, according to studies:

1. 1. The activation of PPARβ/δ appears to lower the risk of age-related macular degeneration (AMD). 
   2. In rats with oxygen-induced retinal damage, GW0742 promoted healing of the eye tissues. 

Related Products:

 
 
Product photos:

 
 
Certificates:
 

 
Company:
 

 
 
FAQ: